

SCIENTIFIC REPORTS

OPEN

OM-85 is an immunomodulator of interferon- β production and inflammasome activity

Received: 05 October 2016

Accepted: 30 January 2017

Published: 06 March 2017

A. T. Dang¹, C. Pasquali², K. Ludigs^{1,†} & G. Guarda¹

The inflammasome–IL-1 axis and type I interferons (IFNs) have been shown to exert protective effects upon respiratory tract infections. Conversely, IL-1 has also been implicated in inflammatory airway pathologies such as asthma and chronic obstructive pulmonary disease (COPD). OM-85 is a bacterial extract with proved efficacy against COPD and recurrent respiratory tract infections, a cause of co-morbidity in asthmatic patients. We therefore asked whether OM-85 affects the above-mentioned innate immune pathways. Here we show that OM-85 induced interferon- β through the Toll-like receptor adaptors Trif and MyD88 in bone marrow-derived dendritic cells. Moreover, it exerted a dual role on IL-1 production; on the one hand, it upregulated proIL-1 β and proIL-1 α levels in a MyD88-dependent manner without activating the inflammasome. On the other hand, it repressed IL-1 β secretion induced by alum, a well-known NLRP3 activator. *In vivo*, OM-85 diminished the recruitment of inflammatory cells in response to peritoneal alum challenge. Our findings therefore suggest that OM-85 favors a protective primed state, while dampening inflammasome activation in specific conditions. Taken together, these data bring new insights into the mechanisms of OM-85 action on innate immune pathways and suggest potential explanations for its efficacy in the treatment of virus-induced airway diseases.

Inflammatory airway diseases are an emerging health problem with high incidence in developed countries. Two important examples are chronic obstructive pulmonary disease (COPD) and asthma. Both disorders are characterized by narrowing of the airways and by a strong inflammatory component¹. Multiple mediators have been implicated in the development of these pathologies, as in particular T helper type (Th)2 cytokines¹. However, significant alterations of innate immune cytokines have also been associated with these disorders. Asthmatic patients show decreased production of type I and III interferons (IFNs), which augments susceptibility to virally induced asthma exacerbations^{2–6}. IFNs are important antiviral and immunomodulatory cytokines, promoting control of respiratory infections while reducing collateral damage and excessive inflammation^{2–12}. In fact, viral infections early in life, but also at later stages, are increasingly recognized as predisposing or aggravating events of asthmatic manifestations^{13–15}.

Interestingly, also several links between interleukin (IL)-1 and inflammatory airway diseases have been established^{16,17}. IL-1 α and IL-1 β are strong inflammatory cytokines, sharing the common IL-1 receptor. Whereas IL-1 α does not require processing for activity, IL-1 β is synthesized as a biologically inactive precursor, called proIL-1 β , and requires cleavage by the protease caspase-1 to be converted into its active form¹⁸. The activation of caspase-1 takes place within a protein complex known as “inflammasome”, which is formed by a nucleating sensor protein, an adaptor protein called apoptosis-associated speck-like protein containing a CARD (ASC), and caspase-1^{18,19}. Several receptors of the NOD-like receptor (NLR) family have been shown to assemble inflammasome platforms, including the intensively studied NLRP3^{19,20}. NLRP3 is well expressed and best studied in innate immune cells and senses a plethora of stimuli encompassing particulate stimuli, pore-forming toxins, and pathogens of fungal, bacterial, as well as viral origin^{18–21}. In addition, AIM2, which is mainly expressed in immune cells, nucleates a well-characterized inflammasome upon recognition of cytoplasmic double-stranded DNA^{18,22}.

These two sensors, are of particular interest with regard to antiviral and inflammatory reactions in the lung^{16,23–27}. Upon influenza infection, NLRP3 inflammasome activation in lung dendritic cells (DCs) and macrophages exerts a protective effect, whereas its overactivation contributes to severe pathophysiology^{23–27}. Similarly,

¹Department of Biochemistry, University of Lausanne, Epalinges, Switzerland. ²Vifor-Pharma c/o OM Pharma SA, 1217 Meyrin 1/Geneva, Switzerland. [†]Present address: Roche Pharma (Schweiz) AG, Schöneggstrasse 2, 4153 Reinach, Switzerland. Correspondence and requests for materials should be addressed to G.G. (email: Greta.Guarda@unil.ch)




Figure 1. OM-85 promotes the production of type I IFN. (a and b) Wild type (WT) BMDCs were stimulated with the indicated doses of OM-85 (a) or Wild type (WT), *Trif*^{-/-}, and *MyD88*^{-/-} BMDCs were stimulated with 320 μg/ml OM-85 (b) for 16 hours (h). IFN-β secretion was measured by ELISA. Results represent mean ± SD (n = 3 technical replicates) and are representative of at least four (a) and two (b) independent experiments. Statistical differences were calculated between the condition without OM-85 (0) and each of the following doses using Student's t-test adjusted by Bonferroni correction over 5 (a) and between the wild type condition and the mutant genotypes using Student's t-test adjusted by Bonferroni correction over 2 (b). ns, non-significant; ***p ≤ 0.001.

in models of pulmonary fibrosis and silicosis, a detrimental role for the NLRP3/IL-1 axis was witnessed^{116,28–39}. The overall contribution of inflammasome and IL-1 to airway pathologies remains therefore multifaceted, exerting protective effects in the context of viral infections, but also harmful ones in chronic inflammatory conditions.

From the medical standpoint, recurrent respiratory tract infections (RTIs), COPD, as well as wheezing and asthma are major public health problems. Concomitantly, prevalence of antibiotic resistance among common respiratory pathogens has recently risen, highlighting the need to develop strategies of immunization against respiratory bacteria and viruses^{40–42}. Launched more than 30 years ago, OM-85 (Broncho-Vaxom®, Broncho-Munal®, Ommunal®, Paxoral®, Vaxoral®), an oral medicine of biological origin used for the prevention of recurrent RTIs and/or exacerbations in at-risk populations, was shown to be effective and safe in both children and adults^{43–47}. Its active principle, an extract of bacterial lysates isolated from 21 known respiratory pathogenic strains, showed protection against airway infections of bacterial and viral origin. In particular, several studies highlighted the capacity of OM-85 to trigger immunomodulatory and protective immune responses against diverse pathogens *in vivo*^{48–54}, including influenza and respiratory syncytial virus as well bacterial superinfection following influenza^{55,56}.

Despite these findings, the effects of OM-85 on the production of type I interferons or inflammasome-mediated IL-1 production have not been assessed. We thus dissected the role of OM-85 in regulating these pathways *in vitro*. We found that OM-85 induced IFN-β production and acted as an effective priming agent inducing substantial levels of proIL-1α and β. Surprisingly, OM-85 also interfered with inflammasome activity specifically in response to alum. These results suggest that OM-85 dampens selected inflammatory reactions, while potentiating innate immune defenses, two effects that might contribute to reducing infections and alleviating COPD and asthmatic conditions in the context of the respiratory tract.

Results

OM-85 induces interferon-β production. Given the potential relevance of type I IFN in asthmatic patients, we investigated the ability of OM-85 to induce this cytokine. We focused on DCs, which are proficient in producing type I IFNs and in activating the inflammasome pathway^{21,25,26}. We therefore treated bone marrow-derived DCs (BMDCs) for 16 hours and assessed IFN-β release in the supernatant. IFN-β production was detected and followed a bell-shaped curve as a function of OM-85 concentration (Fig. 1a). To gain insights into the OM-85-dependent mechanisms inducing IFN-β, we took advantage of *Trif*- and *MyD88*-deficient BMDCs. Interestingly, the absence of either *Trif* or *MyD88* drastically affected OM-85-driven IFN-β production (Fig. 1b). Taken together, we show here that OM-85 has the ability to induce IFN-β production, an important cytokine playing immunomodulatory and antiviral effects, in a *MyD88*- and *Trif*-dependent manner.

OM-85 does per se not lead to IL-1 release. We next tested the effects of OM-85 on the inflammasome/IL-1 axis. Given the complex nature of OM-85, we first asked whether this extract exhibited the capacity to induce IL-1β and α production. This encompasses the steps of inducing their precursor forms, referred to as “priming”, and of activating the inflammasome for their cleavage and/or secretion. We therefore treated BMDCs with increasing doses of OM-85 for either 6 or 16 hours and measured the release of IL-1β and IL-1α by ELISA. As shown in Fig. 2a and b, no substantial production of these cytokines was observed as compared to the unstimulated condition, whereas they were nicely released upon standard two-step stimulation performed by LPS-mediated priming and the NLRP3 inflammasome activator aluminium (alum). This indicates that OM-85 has not *per se* the capacity to induce the inflammasome/IL-1 cascade.

OM-85 acts as a priming signal mainly through *MyD88*. Despite the inability to induce IL-1 secretion, the bacterial origin of OM-85 suggested it to be able to act as a priming signal. We therefore tested its ability to prime BMDCs, which were then treated with alum. As shown in Fig. 3a and b, exposure to OM-85 effectively induced the production of IL-1β and IL-1α by alum-triggered BMDCs. We thus tested the induction of proIL-1β




Figure 2. OM-85 does not activate the inflammasome. (a and b) Dose-response and time course (6 and 16h) for the release of IL-1 β (a) and IL-1 α (b) by BMDCs in response to the indicated concentrations of OM-85 as measured by ELISA. As control, stimulation was performed with LPS (100 ng/ml) for 6 and 16h or LPS (100 ng/ml) followed by addition of alum (300 μ g/ml) for the last 2.5h. Results represent mean \pm SD (n = 3 technical replicates) and are representative of two independent experiments. us = unstimulated (a and b). Statistical differences were calculated between the unstimulated condition and the other conditions by Student's t-test adjusted by Bonferroni correction over 6 (a and b). nd, non-detected; ns, non-significant; **p \leq 0.01; ***p \leq 0.001.

and proIL-1 α in BMDCs upon a four hours treatment with OM-85. As shown in Fig. 3c, the bacterial extract increased the amount of proIL-1 α and proIL-1 β in a dose-dependent manner.

Next, we used *Trif*- and *MyD88*-deficient BMDCs to understand whether these adaptor proteins mediated OM-85-induced proIL-1 β and proIL-1 α . Whereas the absence of *Trif* only slightly affected the levels of proIL-1 α , *MyD88* deficiency abolished OM-85-induced priming with regard to both proIL-1 β and proIL-1 α (Fig. 3c). These data indicate that OM-85 did not deploy toxic effects even at high concentrations and was active, modulating pro-IL-1 β and α in a *MyD88*-dependent manner.

OM-85 acts as a priming signal for the NLRP3 and the AIM2 inflammasomes. We next asked whether OM-85 was an effective priming agent for multiple activators of the NLRP3 as well as for the AIM2 inflammasome, as both these platforms are important for detection of and protection from viral infections. To address these questions, BMDCs pre-treated for four hours with different doses of OM-85 were exposed to the particulate NLRP3 activators alum and monosodium urate (MSU) crystals as well as to the soluble activators ATP and nigericin. As illustrated in Fig. 4a and b, OM-85 was an efficient priming signal for all of these stimuli. While the effects by OM-85 treatment were consistent in all experiments, it is important to mention that the activity of OM-85 on BMDC was subject to some variation, as illustrated here between panels 3a/b and 4a/b at the lower doses applied (e.g. 10 μ g/ml).

In addition, we observed that OM-85 acted in the same way for the AIM2 inflammasome (Fig. 4c and d). Intriguingly however, BMDCs pre-treated with the highest tested dose of OM-85 showed reduced production of IL-1 α and IL-1 β upon polyA:dT-mediated activation.

OM-85 pre-treatment interferes with LPS and alum-induced inflammasome activation. The observation that high-dose OM-85 induced a decrease of AIM2-mediated IL-1 α and IL-1 β release prompted us to further explore potential dampening effects of OM-85 on inflammasome activity. We therefore performed a modified version of the inflammasome activation assay in which we pre-treated BMDCs overnight with OM-85 and added LPS for four hours, followed by inflammasome activators. Whereas we did not observe significant inhibitory effects on IL-1 α and IL-1 β secretion upon inflammasome triggering by ATP, we found that IL-1 β secretion induced by alum and – to a smaller extent by MSU – was downmodulated by OM-85 pre-treatment (Fig. 5a and Supplementary Figure 1a). However, secreted IL-1 α was not substantially decreased, as shown in Fig. 5b. In order to explain the reduced release of IL-1 β , we checked the levels of cleaved caspase-1. Interestingly, caspase-1 activation was decreased by overnight OM-85 pre-treatment (Fig. 5c and Supplementary Figure 1b). Taken together, these data suggests that OM-85 pre-treatment dampens IL-1 β production, at least partly through reducing inflammasome activity in response to alum.

Alum-driven peritonitis is reduced by OM-85. Based on the previous finding, we then tested whether the immunomodulatory effects of OM-85 on the inflammasome were recapitulated in an *in vivo* model. We focused on the well-established alum-dependent peritonitis model, which is mediated by IL-1 α and IL-1 β and is commonly used to assess inflammasome activity *in vivo*¹⁹. Wild type mice were pre-treated intravenously with OM-85, or PBS as control and, five hours later, injected intraperitoneally (i.p.) with alum. Twelve hours post alum-injection, mice were sacrificed and peritoneal exudate cells analyzed by flow cytometry. As depicted in Fig. 6a, a remarkable decrease in the numbers of recruited cells was observed. In addition, when specifically assessing the abundance of individual inflammatory subsets, a significant decrease in the numbers of neutrophils, eosinophils, as well as macrophages was observed (Fig. 6b–d). These data indicate that OM-85 has the ability of interfering also *in vivo* with alum-induced inflammatory reactions.




Figure 3. OM-85 is a priming signal for alum-dependent inflammasome activation. (a and b) BMDCs were primed with 10 ng/ml LPS or the indicated doses of OM-85 for 4 h, followed by inflammasome activation with alum (300 μg/ml) for 2.5 h. Release of IL-1β (a) and IL-1α (b) was measured by ELISA. Results represent mean ± SD (n = 3 technical replicates) and are representative of at least four independent experiments (a and b). Statistical differences were calculated between the LPS only condition and the other conditions by Student's t-test adjusted by Bonferroni correction over 5 (a and b). nd, non-detected; ns, non-significant; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. Wild type (WT), *Trif*^{-/-}, and *MyD88*^{-/-} (c) BMDCs were primed with 10 ng/ml LPS or the indicated doses of OM-85 for 4 h. Levels of proIL-1β, proIL-1α, pro-caspase 1, and tubulin as control, were assessed in cell extracts by immunoblot analysis. Results are representative of two (c) independent experiments. us = unstimulated.

Discussion

Here we have provided evidence for the immunomodulatory effects of OM-85 on the production of two cytokines playing key roles in lung infections and diseases: type I interferons and IL-1. We found that OM-85 was able to induce IFN-β at an optimal intermediate concentration but less at higher doses. Interestingly, these data are reminiscent of results obtained with other inducers of type I IFNs, including DNA, RNA, and fungal pathogen-derived molecular patterns, which show a bell-shaped dose-response curve^{57–60}. These findings suggested that OM-85-triggered IFN production was compatible with TLR stimulation, a hypothesis that was corroborated by the dependency on both TLR adaptor proteins Trif and MyD88. The ability of OM-85 to induce type I IFN was also observed – to a smaller extent – in human DCs⁶¹. This represents an important feature potentially involved in the beneficial effects of OM-85 in airway inflammatory diseases, as IFN is a well-known antiviral cytokine, contributing to minimize the occurrence of various respiratory tract infections and the subsequent exacerbations of chronic inflammatory conditions^{62,63}.

Whereas OM-85 did not activate the inflammasome *per se*, it nicely primed BMDCs, significantly rising proIL-1α and proIL-1β levels, in agreement with data in human DCs⁶¹. Furthermore, our results showed that MyD88 was necessary to augment the levels of proIL-1α and proIL-1β, which are canonical NF-κB targets, downstream of OM-85. Along these lines, previous findings showed a central role for TLRs, MyD88, and activation of downstream NF-κB signaling by OM-85^{48,51,61}. In addition, we show here the involvement of the adaptors MyD88 and Trif in the induction of type I IFN, inferring the implication of TLR3 or TLR4 upon OM-85 treatment⁵¹.

In this work we focused on two inflammasome platforms relevant in the context of antiviral responses, and, in particular, of airway infections: AIM2 and NLRP3^{16,23–27}. We showed that OM-85 exposure efficiently pre-activated BMDCs, an effect that was also demonstrated for *proIL-1β* transcript level on human DCs, for subsequent inflammasome activation and IL-1 production⁶¹. Given the role of the NLRP3 inflammasome and recent data proving the efficacy of OM-85 in controlling influenza infection, it is conceivable that part of the protective effect of OM-85 is mediated by priming of the inflammasome–IL-1 axis^{16,23–27,56}. Our results indicate therefore that OM-85 treatment keeps innate immune cells in an “alerted state” ideal to release large amounts of IL-1 upon sensing an inflammasome trigger and, conceivably, to reduce selected viral infections.

Yet, the pre-activated state induced by OM-85 in BMDCs is not “inflammatory” *per se*, as negligible release of IL-1 is measured under these conditions. This is an important aspect when considering the detrimental effects of IL-1 on chronic inflammatory diseases¹. It therefore seems that OM-85 has the ability to boost inflammation, but exclusively when specific activators of the inflammasome are present. Interestingly, we noticed that the effects of OM-85 on priming, particularly at low doses, diverged in response to different inflammasome activators. In general, activators inducing lower levels of IL-1 release, such as alum, required higher doses of OM-85, indicating a stronger dependency on priming.

Interestingly, we also observed that an overnight pre-treatment with OM-85 dampened the release of IL-1β induced by canonical LPS and alum stimulation. This inhibitory activity was in part due to a reduced activation of caspase-1. These *in vitro* results were corroborated by *in vivo* data showing that OM-85 pre-treatment




Figure 4. OM-85 is a priming signal for multiple inflammasomes. (a and b) BMDCs were primed with 10 ng/ml LPS or the indicated doses of OM-85 (referring to $\mu\text{g/ml}$) for 4 h, followed by stimulation with alum (300 $\mu\text{g/ml}$), MSU (300 $\mu\text{g/ml}$), nigericin, (0.1 μM) for 2.5 h and ATP (500 μM) for 45 min. Release of IL-1 β and IL-1 α was measured by ELISA. (c and d) BMDCs were primed as described above, followed by transfection of poly(dA:dT) (0.6 μg). 6 h after, release of IL-1 β (c) and IL-1 α (d) in the supernatants was measured by ELISA. Results represent mean \pm SD ($n = 3$ technical replicates) and are representative of at least three (a and b) and two (c and d) independent experiments. us = unstimulated. Statistical differences were calculated between the condition exposed to the inflammasome activator only (Alum, MSU, ATP, or Nigericin in the absence of LPS) and the conditions treated with LPS or OM-85 and the inflammasome activator by Student's t-test adjusted by Bonferroni correction over 4 (a and b). Statistical differences were calculated between the condition exposed to poly(dA:dT) in the absence of LPS and the conditions treated with LPS or OM-85 and poly(dA:dT) as well as between the condition treated by LPS and poly(dA:dT) and by OM-85 (1000 $\mu\text{g/ml}$) and poly(dA:dT) using Student's t-test adjusted by Bonferroni correction over 5 (c and d). * $p \leq 0.05$; ** $p \leq 0.01$; *** $p \leq 0.001$.

substantially interferes with an IL-1-driven peritonitis model. It is important to stress that *in vivo* i.p. treatment with alum is sufficient for the secretion of IL-1 α and IL-1 β , indicating that their precursor proteins are synthesized in response to endogenous priming stimuli. As we showed, OM-85 was *per se* able to pre-activate BMDCs for inflammasome activation and IL-1 production, suggesting therefore that its immunomodulatory nature renders it activatory in the absence of additional priming signals and – to some extent – inhibitory in their presence. It was however surprising to see that this effect was quite specific to alum and observed upon activation by MSU only when OM-85 was used at very high doses. This indicates that, besides clear differences between soluble and particulate activators³², more subtle distinctions exist among the latter, which might reside in their chemical or physical properties, including their size.

Despite a significant body of literature demonstrating that the inflammasome pathway exerts multiple and important functions in the pathophysiology of airway diseases, whether OM-85 regulates such cellular responses remained unanswered. Derived from common human bacterial respiratory tract pathogens and used for the prevention of airway infections and chronic inflammation, OM-85 exhibits the capacity to modulate inflammasome responses. Our data suggest that the mode of action of OM-85 with regard to the IL-1 pathway is twofold. On the one hand, it dampens IL-1 β production in response to alum. This effect might be important to prevent selected inflammatory reactions also in the lung, where OM-85 was previously shown to reduce inflammation⁴⁸. On the other hand, OM-85 clearly supports adequate IL-1 production in the case of inflammasome activation. This effect might contribute to the protective effects of OM-85 in the presence of viruses controlled by the inflammasome⁵⁶.

Experimental procedures

Immunoblot analysis. The antibody against mouse IL-1 β was a gift from R. Solari (Imperial College, London), whereas the antibody against mouse caspase-1 was a gift from P. Vandenaebale (Ghent University, Belgium)^{64,65}. Other antibodies used were monoclonal anti-tubulin from Sigma-Aldrich; rabbit polyclonal anti-body to β -actin from Abcam; anti-IL-1 α (ALF161) from ebioscience.




Figure 5. OM-85 dampens IL-1 β release induced by LPS priming and alum. (a–c) BMDCs were pre-treated overnight with the indicated doses of OM-85 ($\mu\text{g/ml}$), primed with 10 ng/ml LPS for 4 h and then treated with 300 $\mu\text{g/ml}$ alum for 2.5 h. Release of IL-1 β (a) and IL-1 α (b) was measured by ELISA. Results represent mean \pm SD ($n = 3$ technical replicates) (a and b). An illustration of all experiments performed is provided in Supplementary Figure 1a. (c) Levels of cleaved IL-1 β and caspase 1 were assessed in culture supernatant by immunoblot analysis, whereas pro-IL-1 β , pro-IL-1 α , pro-caspase 1, and tubulin as control, were assessed in cell extracts. Results are representative of at least three independent experiments. Statistical significance was calculated between the condition treated with LPS and alum and the conditions pre-treated with various doses of OM-85 using Student's *t*-test adjusted by Bonferroni correction over 4 (a,b). ns, non-significant; ** $p \leq 0.01$; *** $p \leq 0.001$.

Mice. Six- to 12-wk-old C57BL/6, *Trif*^{-/-66}, and *MyD88*^{-/-67} mice were housed at the animal facility of the University of Lausanne. All animal experimental protocols were approved by the Veterinary office regulations of the State of Vaud, Switzerland, and all methods were performed in accordance with the Swiss guidelines and regulations.

OM-85 formulation. OM-85 is produced at OM Pharma SA, Meyrin 1/Geneva, Switzerland. Bacteria are grown in individual batches, heat inactivated once they reach a critical mass, harvested, and then subject to alkaline lysis. After lysis, the lysates from the 21 different bacterial strains are mixed together, filtered, and the soluble fraction is neutralized. OM-85 active principle is an alkaline aqueous soluble extract obtained by micro-filtration of the pooled 21 bacterial lysates of *Haemophilus influenzae* (1 strain), *Streptococcus pneumoniae* (4 strains), *Klebsiella pneumoniae* subsp. *pneumoniae* (2 strains), *Klebsiella pneumoniae* subsp. *ozaenae* (1 strains), *Staphylococcus aureus* (6 strains), *Streptococcus pyogenes* (1 strains), *Streptococcus sanguinis* (3 strains), *Moraxella (Branhamella) catarrhalis* (3 strains) with the following characteristics: 24 mg dry weight bacterial extract per mL. The oral formulation is the isotonic OM-85 bacterial extract neutralized at pH 7.0 using HCl 1 M.

In vitro stimulation experiments. BMDCs were differentiated as previously described⁶⁸. For normal stimulation experiments, 7×10^4 differentiated BMDCs were plated in DC differentiation medium (RPMI 1640, 10% FCS, 100 U/ml penicillin, 100 $\mu\text{g/ml}$ streptomycin, 50 μN 2-ME, 10 mM HEPES, supplemented with 20 ng/ml rGM-CSF (ImmunoTools)) and treated for the indicated times and with the indicated doses of OM-85 of




Figure 6. OM-85 hinders recruitment of inflammatory cells upon alum-induced peritoneal inflammation. (a–d) C57BL/6 mice were injected intravenously with the indicated dose of OM-85 or PBS as a control. 5 h later, mice were challenged intraperitoneally with 350 μ g of alum. 12 h after alum injection, mice were sacrificed and peritoneal lavages were performed. Absolute numbers of peritoneal exudate cells (PECs) (a), neutrophils (b), eosinophils (c), and macrophages (d) recruited to the peritoneal cavity are depicted. Results represent mean \pm SEM (n = 7 mice per group) and are a pool of two experiments and are representative of four independent experiments. Statistical significance between control and OM-85-treated mice was calculated using Student's t-test. **p \leq 0.01; ***p \leq 0.001.

ultrapure LPS (Invivogen). For inflammasome activation experiments, 7×10^4 differentiated BMDCs were primed with 10 ng/ml ultrapure LPS or the indicated doses of OM-85 for the 4 h preceding inflammasome stimulations or left unprimed. Then, stimulations were carried out. ATP (500 μ M) and nigericin (0.1 μ M) were from Sigma, MSU crystals (300 μ g/ml) were from Adipogen, and alum (300 μ g/ml) from Pierce Biochemicals (Imject-alum). ATP stimulations were performed for 45 min and other stimulations for 150 min. For the stimulation of the AIM2 inflammasome, poly(dA:dT) (purchased from Invivogen) was admixed at the indicated concentrations to Lipofectamine 2000 (from Invitrogen) according to manufacturer's instructions and cells were stimulated for 6 h. For inflammasome inhibition experiments, 7×10^4 differentiated BMDCs were incubated for 12 h or the indicated times in the presence of OM-85. Cells were then primed with 10 ng/ml ultrapure LPS for the 4 h preceding inflammasome stimulations. Then, stimulations were carried out with the doses of inflammasome activators indicated in the text.

In vivo peritonitis experiments. For peritonitis, mice were injected i.v., with 2.5 mg OM85 followed 5 h later by an i.p. injection of 350 μ g alum (Pierce). 12–14 h after alum injection, mice were sacrificed and peritoneal cavities were washed with 6 ml PBS. PECs were counted and analyzed by flow cytometry using a combination of antibodies against CD11b (M1/70), Ly6C (AL-21), Ly6G (1A8) (BD Pharmingen), antiCD16/32 (93), CD11c (N418), F4/80 (BM8) (eBioscience). For cellular subtype analysis the following gating strategies were used: neutrophils (CD11b⁺, Ly6G^{high}, F4/80⁻), eosinophils (CD11b⁺, SSC^{high}) and macrophages (Ly6G⁻, SSC^{low}, CD11b⁺, F4/80⁺), recruitment was analyzed on a FACSCanto (BD Bioscience) by using the FLOWJO software (Tree Star).

ELISA. Cell culture supernatants were assayed for mouse IL-1 β , IL-1 α (ebioscience), and IFN- β (PBL Assay Science) according to manufacturer's instructions.

Statistical analysis. Statistical analyses were calculated as described in the Figure legends (GraphPad Prism version 5.0).

References

- Barnes, P. J. The cytokine network in asthma and chronic obstructive pulmonary disease. *The Journal of clinical investigation* **118**, 3546–3556 (2008).
- Wark, P. A. *et al.* Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *The Journal of experimental medicine* **201**, 937–947 (2005).
- Contoli, M. *et al.* Role of deficient type III interferon-lambda production in asthma exacerbations. *Nature medicine* **12**, 1023–1026 (2006).
- Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nature reviews. Immunology* **5**, 375–386 (2005).
- Ludigs, K., Parfenov, V., Du Pasquier, R. A. & Guarda, G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. *Cell Mol Life Sci* **69**, 3395–3418 (2012).
- Simon, H. U., Seelbach, H., Ehmann, R. & Schmitz, M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. *Allergy* **58**, 1250–1255 (2003).
- Kumagai, Y. *et al.* Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. *Immunity* **27**, 240–252 (2007).
- Shahangian, A. *et al.* Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. *The Journal of clinical investigation* **119**, 1910–1920 (2009).
- Goritzka, M. *et al.* Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. *The Journal of experimental medicine* **212**, 699–714 (2015).

10. Meissner, N., Swain, S., McInnerney, K., Han, S. & Harmsen, A. G. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. *The American journal of pathology* **176**, 2806–2818 (2010).
11. Arimori, Y. *et al.* Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. *Antiviral research* **99**, 230–237 (2013).
12. Zdrenghea, M. T., Makrinioti, H., Muresan, A., Johnston, S. L. & Stanciu, L. A. The role of macrophage IL-10/innate IFN interplay during virus-induced asthma. *Reviews in medical virology* **25**, 33–49 (2015).
13. Martinez, F. D. The connection between early life wheezing and subsequent asthma: The viral march. *Allergologia et immunopathologia* **37**, 249–251 (2009).
14. Sly, P. D., Kusel, M. & Holt, P. G. Do early-life viral infections cause asthma? *The Journal of allergy and clinical immunology* **125**, 1202–1205 (2010).
15. Murray, C. S., Simpson, A. & Custovic, A. Allergens, viruses, and asthma exacerbations. *Proceedings of the American Thoracic Society* **1**, 99–104 (2004).
16. De Nardo, D., De Nardo, C. M. & Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. *The American journal of pathology* **184**, 42–54 (2014).
17. Ather, J. L., Martin, R. A., Ckless, K. & Poynter, M. E. Inflammasome Activity in Non-Microbial Lung Inflammation. *Journal of environmental immunology and toxicology* **1**, 108–117 (2014).
18. Schroder, K. & Tschopp, J. The inflammasomes. *Cell* **140**, 821–832 (2010).
19. Gross, O., Thomas, C. J., Guarda, G. & Tschopp, J. The inflammasome: an integrated view. *Immunological reviews* **243**, 136–151 (2011).
20. Rathinam, V. A. & Fitzgerald, K. A. Inflammasome Complexes: Emerging Mechanisms and Effector Functions. *Cell* **165**, 792–800 (2016).
21. Guarda, G. *et al.* Differential Expression of NLRP3 among Hematopoietic Cells. *Journal of immunology* **186**, 2529–2534 (2011).
22. Xiao, T. S. The nucleic acid-sensing inflammasomes. *Immunological reviews* **265**, 103–111 (2015).
23. Lupfer, C., Malik, A. & Kanneganti, T. D. Inflammasome control of viral infection. *Current opinion in virology* **12**, 38–46 (2015).
24. Allen, I. C. *et al.* The NLRP3 inflammasome mediates *in vivo* innate immunity to influenza A virus through recognition of viral RNA. *Immunity* **30**, 556–565 (2009).
25. Thomas, P. G. *et al.* The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. *Immunity* **30**, 566–575 (2009).
26. Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R. & Iwasaki, A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. *The Journal of experimental medicine* **206**, 79–87 (2009).
27. McAuley, J. L. *et al.* Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. *PLoS pathogens* **9**, e1003392 (2013).
28. Gasse, P. *et al.* IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. *The Journal of clinical investigation* **117**, 3786–3799 (2007).
29. Gasse, P. *et al.* Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. *American journal of respiratory and critical care medicine* **179**, 903–913 (2009).
30. Kuipers, M. T. *et al.* Ventilator-induced lung injury is mediated by the NLRP3 inflammasome. *Anesthesiology* **116**, 1104–1115 (2012).
31. Dostert, C. *et al.* Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. *Science* **320**, 674–677 (2008).
32. Hornung, V. *et al.* Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nature immunology* **9**, 847–856 (2008).
33. Dostert, C., Ludigs, K. & Guarda, G. Innate and adaptive effects of inflammasomes on T cell responses. *Current opinion in immunology* **25**, 359–365 (2013).
34. Okada, S. *et al.* Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. *J Allergy Clin Immunol* **95**, 1236–1245 (1995).
35. Schmitz, N., Kurrer, M. & Kopf, M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. *Eur J Immunol* **33**, 991–1000 (2003).
36. Nakae, S. *et al.* IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. *Int Immunol* **15**, 483–490 (2003).
37. Li, T. *et al.* Pharmacokinetics and anti-asthmatic potential of non-parenterally administered recombinant human interleukin-1 receptor antagonist in animal models. *J Pharmacol Sci* **102**, 321–330 (2006).
38. Kool, M., Fierens, K. & Lambrecht, B. N. Alum adjuvant: some of the tricks of the oldest adjuvant. *J Med Microbiol* **61**, 927–934 (2012).
39. Allen, I. C. *et al.* Analysis of NLRP3 in the development of allergic airway disease in mice. *Journal of immunology* **188**, 2884–2893 (2012).
40. Holt, P. G. *et al.* Drug development strategies for asthma: in search of a new paradigm. *Nature immunology* **5**, 695–698 (2004).
41. Spellberg, B., Bartlett, J. G. & Gilbert, D. N. The future of antibiotics and resistance. *The New England journal of medicine* **368**, 299–302 (2013).
42. Karchmer, A. W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US—an update. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* **39** Suppl 3, S142–150 (2004).
43. Paupe, J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. *Respiration; international review of thoracic diseases* **58**, 150–154 (1991).
44. Collet, J. P. *et al.* Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group. *The Pediatric infectious disease journal* **12**, 648–652 (1993).
45. Schaad, U. B., Mutterlein, R., Goffin, H. & Group, B. V.-C. S. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. *Chest* **122**, 2042–2049 (2002).
46. Razi, C. H. *et al.* The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. *The Journal of allergy and clinical immunology* **126**, 763–769 (2010).
47. Schaad, U. B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. *World journal of pediatrics: WJP* **6**, 5–12 (2010).
48. Navarro, S. *et al.* The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. *Mucosal immunology* **4**, 53–65 (2011).
49. Fu, R. *et al.* Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3beta-related T regulatory cell insufficiency. *PLoS one* **9**, e92912 (2014).
50. Han, L. *et al.* A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. *American journal of rhinology & allergy* **28**, 110–116 (2014).
51. Luan, H. *et al.* OM85-BV induced the productions of IL-1beta, IL-6, and TNF-alpha via TLR4- and TLR2-mediated ERK1/2/NF-kappaB pathway in RAW264.7 cells. *Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research* **34**, 526–536 (2014).

52. Roth, M. & Block, L. H. Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines. *Thorax* **55**, 678–684 (2000).
53. Huber, M., Mossmann, H. & Bessler, W. G. Th1-orientated immunological properties of the bacterial extract OM-85-BV. *European journal of medical research* **10**, 209–217 (2005).
54. Scott, N. M. *et al.* Protection against maternal infection-associated fetal growth restriction: proof-of-concept with a microbial-derived immunomodulator. *Mucosal immunology* (2016).
55. Bessler, W. G., Vor dem Esche, U. & Masihi, N. The bacterial extract OM-85 BV protects mice against influenza and Salmonella infection. *International immunopharmacology* **10**, 1086–1090 (2010).
56. Pasquali, C. *et al.* Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. *Frontiers in medicine* **1**, 41 (2014).
57. Edwards, S. *et al.* TLR7 stimulation of APCs results in inhibition of IL-5 through type I IFN and Notch signaling pathways in human peripheral blood mononuclear cells. *Journal of immunology* **190**, 2585–2592 (2013).
58. Biondo, C. *et al.* Recognition of yeast nucleic acids triggers a host-protective type I interferon response. *European journal of immunology* **41**, 1969–1979 (2011).
59. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. *Journal of immunology* **170**, 3059–3064 (2003).
60. Waibler, Z. *et al.* Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN- α responses by pDC. *European journal of immunology* **38**, 3127–3137 (2008).
61. Parola, C. *et al.* Selective activation of human dendritic cells by OM-85 through a NF- κ B and MAPK dependent pathway. *PLoS one* **8**, e82867 (2013).
62. Kim, E. Y. *et al.* Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. *Nature medicine* **14**, 633–640 (2008).
63. Ahanchian, H., Jones, C. M., Chen, Y. S. & Sly, P. D. Respiratory viral infections in children with asthma: do they matter and can we prevent them? *BMC pediatrics* **12**, 147 (2012).
64. Van de Craen, M., Declercq, W., Van den Brande, I., Fiers, W. & Vandenaabeele, P. The proteolytic procaspase activation network: an *in vitro* analysis. *Cell death and differentiation* **6**, 1117–1124 (1999).
65. Guarda, G. *et al.* Type I interferon inhibits interleukin-1 production and inflammasome activation. *Immunity* **34**, 213–223 (2011).
66. Yamamoto, M. *et al.* Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* **301**, 640–643 (2003).
67. Adachi, O. *et al.* Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. *Immunity* **9**, 143–150 (1998).
68. Guarda, G. *et al.* T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. *Nature* **460**, 269–273 (2009).

Acknowledgements

We thank N. Fasel, University of Lausanne, Switzerland, R. Solari, Imperial College London, United Kingdom, P. Vandenaabeele, Ghent University, Belgium, and S. Akira, Osaka University, Japan, for sharing mice and reagents with us. We thank the late Prof. Tschopp for having contributed tools essential to this project. This work was funded by a research grant provided by Vifor Pharma, a company of the Galenica Group. Studies in the group of GG are funded by the Swiss National Science Foundation (PP00P3_139094 and PP00P3_165833) and the European Research Council (ERC-2012-StG310890).

Author Contributions

A.D. and K.L. performed the experiments; C.P. and G.G. shared protocols, reagents and advice, designed the research, analyzed the data and wrote the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Dang, A. T. *et al.* OM-85 is an immunomodulator of interferon- β production and inflammasome activity. *Sci. Rep.* **7**, 43844; doi: 10.1038/srep43844 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017